Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Remicade Biosimilar Market?

The market size for remicade biosimilar has witnessed tremendous growth in the past few years. Expected to rise from $3.95 billion in 2024 to $4.89 billion in 2025, it is projected to have a compound annual growth rate (CAGR) of 23.8%. Factors contributing to such significant growth during the historical period include the launch of remicade (infliximab), advancements in biotechnology, the expiry of biologics patents, the establishment of a regulatory pathway, and pressures on healthcare costs.

We predict a substantial increase in the size of the Remicade biosimilar market over the ensuing years, as it is projected to attain a worth of “$10.89 billion by 2029 with a compound annual growth rate (CAGR) of 22.2%. Factors contributing to this prospective growth during the forecast period encompass patent end dates, escalating demand for economically viable treatments, the development of biosimilar pipelines, reimbursement policies, and market unification. Key trends expected to shape this period entail physician’s prescribing habits, biosimilar lifecycle administration, naming protocols for biosimilars, interchangeability of biosimilars, and tangible evidence of biosimilar use in the real-world.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

Which Factors Are Steering Growth In The Remicade Biosimilar Market?

The prevalence increase of autoimmune conditions is anticipated to catapult the development of the remicade biosimilar market. Autoimmune diseases, conditions where the immune system incorrectly damages the body’s tissues and organs, can be managed using remicade biosimilars, which are an effective therapeutic solution for the managing symptoms and reducing the inflammation related to these diseases. For example, Public Health Scotland revealed in July 2023 that there was an increase in the diagnosis of new patients with multiple sclerosis (MS) in 2022, with 491 new cases reported, taking the total to 6,359. This showed an increase to 87.2%, up from 85.7% in 2020. Consequently, the upsurging incidence of autoimmune diseases is propelling the remicade biosimilar market’s growth.

How Is The Remicade Biosimilar Market Organized By Different Segments?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Current And Upcoming Trends Are Shaping The Remicade Biosimilar Market?

In the Remicade biosimilar market, the emerging trend of product innovation is catching everyone’s attention. To maintain their market presence, key companies in this space are heavily investing in product development. For example, in January 2023, Amgen Inc., a biotechnology firm based in the US, introduced Amjevita, an alternative to AbbVie’s Humira, having the same safety and effectiveness as the original medication. As the first-ever biosimilar to Humira, Amjevita is set to give tough competition to Humira in terms of market share. This biosimilar drug is prescribed for dealing with different autoimmune conditions including rheumatoid arthritis and Crohn’s disease. Despite being one of the world’s costliest drugs contributing to billions of dollars in annual revenues for AbbVie, Amjevita is expected to be more cost-effective. Besides the obvious financial benefits, Amjevita may also provide patients with additional treatment alternatives.

Who Are The Global Leaders Steering The Remicade Biosimilar Market Forward?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

How Do Regional Dynamics Influence The Remicade Biosimilar Market Performance?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model